Becoming a Truly Global Specialty Pharma
That Meets the Expectations of Patients Worldwide

Having amassed a significant body of clinical evidence in the field of oncology, Taiho Pharmaceutical has contributed to the establishment of better treatment methods for years now as Japan’s pioneer in developing oral anticancer agents. Since the start of the new millennium, Taiho Pharmaceutical has made every effort to increase its global reach, seeking to bring smiles to the faces of more patients around the world. The company is pursuing global R&D while building its own sales structure in the U.S. and expanding its sales network in other countries.

  • Global Specialty Pharma
  • Research & Development
    Taiho is expanding its pipeline and strengthening its ties with medical and research institutions worldwide in an effort to accelerate drug discovery and development and increase its global presence.
  • Marketing
    Taiho aims to contribute to medical care worldwide by providing innovative new drugs and high-quality information via its global network in the U.S., Europe, and Asia.
  • Production
    Taiho’s production system supplies the world market with safe, high-quality pharmaceuticals that are manufactured to stringent international standards, including those of the U.S. and Europe.


Two Global Cores to Lead Taiho's Global Efforts in Strategy and Corporate Functions

Taiho Pharmaceutical aims to be an agile specialty pharma trusted around the world. In January 2016, a Global Chief Corporate Officer (GCCO) and a Global Chief Medical Officer (GCMO) were appointed to lead the global headquarters effort in corporate functions and portfolio, products and development strategies, respectively. Offices under the GCCO and the GCMO are situated at the Tokyo head office.

Taiho Pharmaceutical Invests US$ 30 Million in Remiges BioPharma Fund, LP to Foster Early Biotech Start-ups

In 2014, Taiho invested in the Remiges BioPharma Fund, LP, an open innovation fund managed by Remiges Ventures, which is located in Boston and Tokyo. The GCMO Office members are part of the Fundʼs US-Japan cross border team. By tapping into the biotech start-up community in the U.S. and Europe, where the latest technical expertise converges, we will be able to access innovative technologies. By becoming a part of the Remiges team, Taiho aims to increase the acumen of its human resources, thus strengthening its drug discovery capabilities.


In 2002, Taiho Pharmaceutical established Taiho Pharma U.S.A., Inc. (now Taiho Oncology, Inc.) to serve as its global development base. During the development of LONSURF, the company made the transition to a fully integrated clinical development and commercial entity. In 2015, the U.S. Food and Drug Administration (FDA) approved LONSURF for the treatment of refractory metastatic colorectal cancer. Taiho Oncology began marketing the product and is expanding sales there.


In 2016, the corporate venture capital company, Taiho Ventures, LLC, was established in California for the purpose of biotechnology investment. It invests in promising biotechnology ventures in the US and elsewhere that are engaged in innovative new drug R&D as well as the development of drug-enabling platform technologies, mainly in the oncology field. It will also utilize the resources Taiho Pharmaceutical has cultivated as a pioneer of oral anticancer drugs and will support the development of its venture companies.


In December 2016, Taiho Pharma Canada, Inc. was established as a new pharmaceutical business base in that country. The company filed a New Drug Submission of LONSURF in May 2017 with Health Canada, the Canadian health authority. The product will be launched there after approval is obtained.


In 2009, Taiho Pharmaceutical established Taiho Pharma Europe, Ltd., to serve as its drug development center in Europe. Teysuno (called TS-1 in Japan) was approved in 2011 in Europe as a treatment for advanced gastric cancer. As of December 2016, Teysuno is available in 19 European countries through Nordic Group BV, the companyʼs Netherlands-based partner.
In June 2015, Taiho entered into a license agreement with Servier (France) for development and commercialization of LONSURF in Europe and other regions (excluding North America and Asia). In April 2016, approval for the drug was granted by the European Commission, and sales are being expanded in countries there.
Going forward, Taiho aims to contribute to the treatment of cancer patients in Europe and other countries through its partnership with Servier.


In 2008, Taiho Pharmaceutical established Taiho Pharmaceutical of Beijing Co., Ltd., to serve as its development and marketing base in China, and in 2011 it established Taiho Pharma of Singapore Pte. Ltd. as a development and marketing base in Southeast Asia.
As of December 2016, TS-1 (known as TS-ONE and other product names locally) is being marketed in ten Asian countries and regions, while UFT and Futraful are both being marketed in two countries and regions either by Taiho or through a business partner.

New Global Leadership Program Launched in 2016

  • Logo image

Global One Academy was established in July 2016 as Taiho Groupʼs corporate university to nurture global leaders who can demonstrate change leadership and solve management issues. “Junior Course,” the first course to be launched, was designed for junior members of the company. The Class of 2017, consisting of 23 members who went through a rigorous selection process to be in the course, are learning basic skills essential for next-generation leaders. These skills include communication skills, critical thinking, problem solving and design thinking. The members are already implementing these skills in their everyday work.


Taiho Pharmaceutical created the TAIHO ONCOLOGY brand to leverage its Japanese reputation worldwide, seeking to increase its global market recognition as a leader in the field of oncology. The company is promoting the brand at academic conferences, pursuing open innovation based on cooperation with farsighted medical professionals and researchers. The TAIHO ONCOLOGY brand stands for the determination to create cancer treatments that will more quickly and more definitely become global standards, for the benefit of patients worldwide.

  • Challenging cancer is our legacy.